These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8411001)

  • 1. Synthesis and relative potencies of new constrained CRF antagonists.
    Hernandez JF; Kornreich W; Rivier C; Miranda A; Yamamoto G; Andrews J; Taché Y; Vale W; Rivier J
    J Med Chem; 1993 Oct; 36(20):2860-7. PubMed ID: 8411001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Astressin analogues (corticotropin-releasing factor antagonists) with extended duration of action in the rat.
    Rivier J; Gulyas J; Corrigan A; Martinez V; Craig AG; Taché Y; Vale W; Rivier C
    J Med Chem; 1998 Dec; 41(25):5012-9. PubMed ID: 9836619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conformationally restricted competitive antagonists of human/rat corticotropin-releasing factor.
    Miranda A; Koerber SC; Gulyas J; Lahrichi SL; Craig AG; Corrigan A; Hagler A; Rivier C; Vale W; Rivier J
    J Med Chem; 1994 May; 37(10):1450-9. PubMed ID: 8182703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Constrained corticotropin-releasing factor (CRF) agonists and antagonists with i-(i+3) Glu-Xaa-DXbb-Lys bridges.
    Koerber SC; Gulyas J; Lahrichi SL; Corrigan A; Craig AG; Rivier C; Vale W; Rivier J
    J Med Chem; 1998 Dec; 41(25):5002-11. PubMed ID: 9836618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single point D-substituted corticotropin-releasing factor analogues: effects on potency and physicochemical characteristics.
    Rivier J; Rivier C; Galyean R; Miranda A; Miller C; Craig AG; Yamamoto G; Brown M; Vale W
    J Med Chem; 1993 Oct; 36(20):2851-9. PubMed ID: 8411000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Constrained corticotropin-releasing factor antagonists with i-(i + 3) Glu-Lys bridges.
    Miranda A; Lahrichi SL; Gulyas J; Koerber SC; Craig AG; Corrigan A; Rivier C; Vale W; Rivier J
    J Med Chem; 1997 Oct; 40(22):3651-8. PubMed ID: 9357532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal-size, constrained corticotropin-releasing factor agonists with i-(i+3) Glu-Lys and Lys-Glu bridges.
    Rivier J; Lahrichi SL; Gulyas J; Erchegyi J; Koerber SC; Craig AG; Corrigan A; Rivier C; Vale W
    J Med Chem; 1998 Jul; 41(14):2614-20. PubMed ID: 9651165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corticotropin releasing factor (CRF) agonists with reduced amide bonds and Ser7 substitutions.
    Cervini L; Theobald P; Corrigan A; Craig AG; Rivier C; Vale W; Rivier J
    J Med Chem; 1999 Feb; 42(4):761-8. PubMed ID: 10052982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constrained corticotropin releasing factor antagonists (astressin analogues) with long duration of action in the rat.
    Rivier JE; Kirby DA; Lahrichi SL; Corrigan A; Vale WW; Rivier CL
    J Med Chem; 1999 Aug; 42(16):3175-82. PubMed ID: 10447963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a novel and potent corticotropin-releasing factor antagonist in rats.
    Menzaghi F; Howard RL; Heinrichs SC; Vale W; Rivier J; Koob GF
    J Pharmacol Exp Ther; 1994 May; 269(2):564-72. PubMed ID: 8182523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor.
    Gulyas J; Rivier C; Perrin M; Koerber SC; Sutton S; Corrigan A; Lahrichi SL; Craig AG; Vale W; Rivier J
    Proc Natl Acad Sci U S A; 1995 Nov; 92(23):10575-9. PubMed ID: 7479843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological comparison of two corticotropin-releasing factor antagonists: in vivo and in vitro studies.
    Curtis AL; Grigoriadis DE; Page ME; Rivier J; Valentino RJ
    J Pharmacol Exp Ther; 1994 Jan; 268(1):359-65. PubMed ID: 8301577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of pituitary and brain receptors for corticotrophin-releasing factor in modulating alcohol-induced ACTH secretion in the rat.
    Rivier C; Rivier J; Lee S
    Brain Res; 1996 May; 721(1-2):83-90. PubMed ID: 8793087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stressin1-A, a potent corticotropin releasing factor receptor 1 (CRF1)-selective peptide agonist.
    Rivier J; Gulyas J; Kunitake K; DiGruccio M; Cantle JP; Perrin MH; Donaldson C; Vaughan J; Million M; Gourcerol G; Adelson DW; Rivier C; Taché Y; Vale W
    J Med Chem; 2007 Apr; 50(7):1668-74. PubMed ID: 17335188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists.
    Rivier J; Gulyas J; Kirby D; Low W; Perrin MH; Kunitake K; DiGruccio M; Vaughan J; Reubi JC; Waser B; Koerber SC; Martinez V; Wang L; Taché Y; Vale W
    J Med Chem; 2002 Oct; 45(21):4737-47. PubMed ID: 12361401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin 1 beta inhibits gastric emptying in rats: mediation through prostaglandin and corticotropin-releasing factor.
    Sütö G; Király A; Taché Y
    Gastroenterology; 1994 Jun; 106(6):1568-75. PubMed ID: 8194703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alanine series of ovine corticotropin releasing factor (oCRF): a structure-activity relationship study.
    Kornreich WD; Galyean R; Hernandez JF; Craig AG; Donaldson CJ; Yamamoto G; Rivier C; Vale W; Rivier J
    J Med Chem; 1992 May; 35(10):1870-6. PubMed ID: 1316969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral injection of a new corticotropin-releasing factor (CRF) antagonist, astressin, blocks peripheral CRF- and abdominal surgery-induced delayed gastric emptying in rats.
    Martínez V; Rivier J; Taché Y
    J Pharmacol Exp Ther; 1999 Aug; 290(2):629-34. PubMed ID: 10411571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats.
    Rodríguez de Fonseca F; Rubio P; Menzaghi F; Merlo-Pich E; Rivier J; Koob GF; Navarro M
    J Pharmacol Exp Ther; 1996 Jan; 276(1):56-64. PubMed ID: 8558457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel high-affinity photoactivatable antagonists of corticotropin-releasing factor (CRF) photoaffinity labeling studies on CRF receptor, type 1 (CRFR1).
    Bonk I; Rühmann A
    Eur J Biochem; 2000 May; 267(10):3017-24. PubMed ID: 10806401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.